[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858-751-4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 63, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 1037500, "exercisedValue": 0, "unexercisedValue": 9922011}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 54, "title": "Chief Technical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 590400, "exercisedValue": 0, "unexercisedValue": 460878}, {"maxAge": 1, "name": "Mr. Byron  Robinson J.D., Ph.D.", "age": 58, "title": "Chief Strategy Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 723000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tighe M. Reardon C.F.A., CPA", "age": 47, "title": "Acting Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tommy  Diraimondo Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Pennington", "title": "General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Brenda  Van Vreeswyk", "title": "Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy Hollman Meyer", "age": 39, "title": "Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 43.91, "open": 43.98, "dayLow": 41.44, "dayHigh": 45.51, "regularMarketPreviousClose": 43.91, "regularMarketOpen": 43.98, "regularMarketDayLow": 41.44, "regularMarketDayHigh": 45.51, "beta": 3.576, "forwardPE": -25.778442, "volume": 522478, "regularMarketVolume": 522478, "averageVolume": 821491, "averageVolume10days": 575370, "averageDailyVolume10Day": 575370, "bid": 43.01, "ask": 43.16, "bidSize": 100, "askSize": 100, "marketCap": 2232172544, "fiftyTwoWeekLow": 5.65, "fiftyTwoWeekHigh": 65.6, "priceToSalesTrailing12Months": 306.32257, "fiftyDayAverage": 44.9426, "twoHundredDayAverage": 26.883425, "currency": "USD", "enterpriseValue": 1604344832, "floatShares": 21168789, "sharesOutstanding": 51850700, "sharesShort": 3574134, "sharesShortPriorMonth": 2986118, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0689, "heldPercentInsiders": 0.094510004, "heldPercentInstitutions": 0.96658, "shortRatio": 3.86, "shortPercentOfFloat": 0.1371, "bookValue": 12.65, "priceToBook": 3.403162, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -55594000, "trailingEps": -1.2, "forwardEps": -1.67, "pegRatio": -0.23, "enterpriseToRevenue": 220.165, "enterpriseToEbitda": -22.652, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "JANX", "underlyingSymbol": "JANX", "shortName": "Janux Therapeutics, Inc.", "longName": "Janux Therapeutics, Inc.", "firstTradeDateEpochUtc": 1623418200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3a638123-d3da-3133-96c7-e6e8cabf84b3", "gmtOffSetMilliseconds": -14400000, "currentPrice": 43.05, "targetHighPrice": 100.0, "targetLowPrice": 47.0, "targetMeanPrice": 68.57, "targetMedianPrice": 64.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 651763008, "totalCashPerShare": 12.571, "ebitda": -70825000, "totalDebt": 24185000, "quickRatio": 61.851, "currentRatio": 62.086, "totalRevenue": 7287000, "debtToEquity": 3.688, "revenuePerShare": 0.159, "returnOnAssets": -0.08741, "returnOnEquity": -0.114980005, "freeCashflow": -33208876, "operatingCashflow": -51501000, "revenueGrowth": -0.389, "operatingMargins": -16.103039, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-19"}]